Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 12, 2024 08:00 ET | Source: Compass Therapeutics

Compass Therapeutics Reports 2024 Third Quarter Financial Results and Provides Corporate Update

Fully enrolled the Phase 2/3 trial of lead asset CTX-009 (DLL4 and VEGF-A bispecific antibody) in patients with biliary tract cancers (BTC); top-line data readout is on track for the end of the first...
August 12, 2024 08:00 ET | Source: Compass Therapeutics

Compass Therapeutics Reports 2024 Second Quarter Financial Results and Provides Corporate Update

Compass Therapeutics announces 2nd quarter results and provides clinical results update
May 13, 2024 08:00 ET | Source: Compass Therapeutics

Compass Therapeutics Reports 2024 First Quarter Financial Results and Provides Corporate Update

Received FDA Fast Track Designation for the investigation of CTX-009 in combination with paclitaxel for the treatment of patients with metastatic or locally advanced biliary tract tumors. Enrollment...
May 09, 2022 08:00 ET | Source: Compass Therapeutics

Compass Therapeutics Reports First Quarter 2022 Financial Results and Highlights Recent Company Progress

The FDA cleared the investigational new drug application for CTX-009 (DLL4 X VEGF-A bispecific) in January allowing the Company to expand the ongoing Phase 2 study in patients with biliary tract...